Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

CHIEF PROD & SUPPLY CHAIN OFF

CHIEF BUSINESS OFFICER

CHIEF OPERATING OFFICER

CHIEF SCIENTIFIC OFFICER

CHIEF EXECUTIVE OFFICER

CHIEF ACCOUNTING OFFICER

CHIEF TECHNOLOGY OFFICER

CHIEF DEVELOPMENT OFFICER

Chief Scientific Officer

Chief Technology Officer

Chief Executive Officer

Chief Accounting Officer

Chief Operating Officer

Chief Business Officer

Chief Development Officer

Chief Financial Officer

President and CFO

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. It is developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; BT5528, a BTC that is in a Phase I/II clinical trial targeting Ephrin type-A receptor 2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. The company also develops THR-149, a plasma kallikrein inhibitor for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA; and BT7401, a multivalent CD137 agonist. In addition, it collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, dementia, central nervous system, neuromuscular, and respiratory indications. The company has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca AB, Sanofi, Oxurion NV, and the Dementia Discovery Fund, as well as with Ionis Pharmaceuticals, Inc.; and a discovery collaboration and license agreement with Genentech Inc. for the discovery and development of Bicycle peptides for multiple immuno-oncology targets, as well as strategic collaboration with Bayer for developing Novel Targeted Radionuclide Therapies in Oncology. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by e...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-18	Premium	acquired	Premium	Premium	Premium	-
2024-04-11	Premium	sold	Premium	Premium	Premium	CHIEF PROD & SUPPLY CHAIN OFF
2024-04-03	Premium	sold	Premium	Premium	Premium	CHIEF BUSINESS OFFICER
2024-04-03	Premium	sold	Premium	Premium	Premium	CHIEF OPERATING OFFICER
2024-04-03	Premium	sold	Premium	Premium	Premium	CHIEF SCIENTIFIC OFFICER
2024-04-03	Premium	sold	Premium	Premium	Premium	CHIEF EXECUTIVE OFFICER
2024-04-03	Premium	sold	Premium	Premium	Premium	CHIEF ACCOUNTING OFFICER
2024-04-03	Premium	sold	Premium	Premium	Premium	CHIEF TECHNOLOGY OFFICER
2024-02-20	Premium	acquired	Premium	Premium	Premium	-
2024-02-06	Premium	acquired	Premium	Premium	Premium	CHIEF DEVELOPMENT OFFICER
2024-01-03	Premium	sold	Premium	Premium	Premium	Chief Scientific Officer
2024-01-03	Premium	sold	Premium	Premium	Premium	Chief Technology Officer
2024-01-03	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2024-01-03	Premium	sold	Premium	Premium	Premium	Chief Accounting Officer
2024-01-03	Premium	sold	Premium	Premium	Premium	Chief Operating Officer
2024-01-03	Premium	sold	Premium	Premium	Premium	Chief Business Officer
2024-01-02	Premium	acquired	Premium	Premium	Premium	Chief Accounting Officer
2024-01-02	Premium	acquired	Premium	Premium	Premium	-
2024-01-02	Premium	acquired	Premium	Premium	Premium	-
2024-01-02	Premium	acquired	Premium	Premium	Premium	Chief Operating Officer
2024-01-02	Premium	acquired	Premium	Premium	Premium	Chief Development Officer
2024-01-02	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-01-02	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2024-01-02	Premium	acquired	Premium	Premium	Premium	Chief Technology Officer
2024-01-02	Premium	acquired	Premium	Premium	Premium	-

BCYC - Bicycle Therapeutics Ltd Stock Price, Fair Value and News

Latest Insider Trading transactions for BCYC